Please enable JavaScript or talk to your local administrator to get JavaScript enabled.
Skip filters
Skip facets
Funder
  • 28

  • 11

  • 8

  • 7

  • 3

  • 3

  • 2

  • 2

  • 2

  • 2

Funder Group
Research Organization
FOR (ANZSRC) Category
RCDC Category
Researcher
City
State
Country
Country of Funder
Start Year
Active Year
Similar Projects for

Project

A Patient-Centered Approach to Integration of Life Expectancy into Treatment Decision Making for Patients with Genitourinary Malignancy

Funder: National Cancer Institute

Funding period
USD 183 K
Funding amount
Abstract
PROJECT SUMMARY Life expectancy (LE) is a critical factor in treatment decision making for men with genitourinary (GU) malignancies, since limited LE predicts lower likelihood of sufficient longevity to benefit from treatment, higher morbidity after treatment, and decreased effectiveness of treatment. Despite a prominent role of LE in guidelines, patients with limited LE are often overtreated for indolent cancers and undertreated for high-risk cancers. Data from non-cancer treatment settings suggest that this may be due to physician-level barriers precluding effective communication of LE. Surprisingly little is known about how LE is currently communicated in treatment consultations as well as patient and physician perspectives on how it should be ideally integrated. Furthermore, patient and community opinions on what LE cutoffs are best suited to ?non-aggressive treatment? are lacking. In this application, we propose a series of incremental studies with an overarching goal of building a patient-centered approach to integrating LE into treatment decision making for patients with prostate, kidney, and bladder cancer. (1) First, we will delineate how LE is currently communicated to patients with GU cancers through qualitative analysis of treatment consultation transcripts of patients with early-stage prostate, kidney, and muscle-invasive bladder cancer. We believe that the current communication of LE will be highly variable in terms of incidence of discussion, mode of communication, temporal positioning within the visit, emotive context, and time devoted to the topic. (2) Second, we will engage patient and specialist physician stakeholders through structured interviews to identify barriers and opportunities to improve communication information about LE in cancer treatment decision making. (3) Third, we will use online crowdsourcing of conjoint analysis (CA) as a platform to study how patients and the community value LE relative to other tradeoffs typically encountered in prostate, kidney, and bladder cancer treatment decision making. We will analyze crowdsourced conjoint analysis data to identify situations (based on age, comorbidity, and tumor risk) where LE appears to drive ?non-aggressive? treatment choices, which will allow for targeting of LE interventions. (4) Fourth, we will test in a randomized trial whether patient-specific LE estimates? communicated in a patient-centered approach as determined in the first and second aims and targeted to specific high-yield situations as identified in the third aim?along with LE-specific conjoint analysis data improve decisional conflict, quality of LE data discussed, and reduce overtreatment of GU malignancies. We anticipate that this patient-centered approach will improve shared decision making and ultimately result in better treatment choices for patients with GU cancers and limited LE.

 
79
Projects
USD 64.1 M
Aggregated funding amount
USD 843 K
Average funding amount
Project list item
Chromatin Modifier Gene Mutation and Enhancer Dysfunction in Bladder Cancer

National Cancer Institute to BYRON H LEE

USD 243,205
2019 - 2024
Project list item
Combatting Bladder Cancer by Inducing Epithelial Turnover

National Cancer Institute to SOMAN N ABRAHAM

USD 203,510
2019 - 2021
Project list item
Novel 3D personalized bladder cancer model on demand: A new era for personalized medicine.

Canadian Institutes of Health Research to Alan I So, Claudia Itze Chavez-munoz

USD 47,959
2018 - 2020
Project list item
New Drug and Technology Assessment in Bladder Cancer: Creation of a Novel Canadian Policy Model for Bladder Cancer

Canadian Institutes of Health Research to Girish Satish Kulkarni, Murray Dale Krahn, Shabbir Muhammad Husayn Alibhai, Peter Colin Black, Wassim Kassouf, Nathan Perlis, George Andrew Tomlinson, William Wai Lun Wong

USD 77,161
2018 - 2019
Project list item
Ty21a immunotherapy of non-muscle-invasive bladder cancer

Swiss National Science Foundation to Denise Nardelli Haefliger

USD 436,670
2018 - 2021
Project list item
CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer

Patient-Centered Outcomes Research Institute to John Gore

USD 8,500,000
2018 - 2022
Project list item
INTRAVESICAL ONCOLYTIC THERAPY FOR BLADDER CANCER

National Cancer Institute to ROSA MARIA DIAZ, LUKKANA SUKSANPAISAN, BRADLEY C. LEIBOVICH

USD 1,081,593
2017 - 2020
Project list item
(PQ3) Immune epigenetic biomarkers of bladder cancer outcomes

National Cancer Institute to BROCK CLARKE CHRISTENSEN

USD 1,235,254
2017 - 2022
Project list item
FrostBite-BC - A New Thermal Ablation Device for Treating Bladder Cancer

National Cancer Institute to J M BAUST

USD 308,550
2017 - 2019
Project list item
The Role of EZH2 in Non-Muscle Invasive Bladder Cancer

United States Department of Veterans Affairs to JOSHUA JAMES MEEKS

 
2016 - 2020
Project list item
Understanding barriers to single-dose intravesical chemotherapy in non-muscle invasive bladder cancer

National Cancer Institute to KELLY CLINTON CARY

USD 433,019
2016 - 2021
Project list item
Regulation of ATDC by TP63 and its role in bladder cancer

National Cancer Institute to PHILLIP L PALMBOS

USD 524,880
2016 - 2021
Project list item
Monitoring Recurrent Bladder Cancer with Electro-Phage Biosensors

National Cancer Institute to GREGORY A. WEISS

USD 932,247
2016 - 2019
Project list item
Pluripotent stem cell-derived bladder epithelial progenitors for definitive cell replacement therapy of bladder cancer

California Institute for Regenerative Medicine to Philip Beachy

USD 1,400,033
2016 - 2016
Project list item
Early clinical testing of intravesical administration of the muco-adherent, docetaxel-laden polymer STK-01 in bladder cancer.

Canadian Institutes of Health Research to Alan I So, Peter Colin Black

USD 225,587
2016 - 2019
Project list item
Notch in bladder cancer: oncogene and tumour suppressor

Canadian Cancer Society to Peter Black, Colin Collins, Mads Daugaard, Yuzhuo Wang

USD 758,595
2016 - 2020
Project list item
High resolution imaging for early and better detection of bladder cancer

Cancer Prevention and Research Institute of Texas to Rebecca R Richards-Kortum

USD 873,765
2015 -
Project list item
Precision Medicine in Platinum-Treated Lethal Bladder Cancer

Congressionally Directed Medical Research Programs to Jonathan Rosenberg

USD 788,605
2015 - 2016
load more...